FDA Brief

Warning letters Drugs

FDA warning letter to

Neva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi

High riskIssued Mar 12, 2025Posted Mar 18, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.

What happened

FDA inspected the facility in Esenyurt, Istanbul, from September 16 to 20, 2024, and reviewed the company’s October 4, 2024 response to the Form FDA 483, the list of inspection observations. FDA found the company did not test each incoming component lot for identity, relied on supplier certificates without verifying their reliability, and lacked process validation, stability testing, and adequate quality-unit oversight. FDA also placed the firm’s products on Import Alert 66-40, which flags products for refusal at the U.S. border, on February 12, 2025.

What FDA found

  1. The company did not perform at least one identity test on each incoming component lot and did not verify the reliability of its suppliers’ test results.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The company failed to test each shipment of each high-risk component lot using the standard limit test that detects hazardous impurities.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The company failed to establish adequate written procedures for production and process control and did not adequately validate its manufacturing processes or qualify equipment.

    21 CFR 211.100(a)
  4. The company failed to establish an adequate stability testing program to show its OTC drugs remain within specifications through their labeled shelf lives.

    21 CFR 211.166(a)
  5. The company’s quality control unit did not provide adequate oversight, including for equipment cleaning and maintenance records, laboratory control procedures, and annual product reviews.

    21 CFR 211.22; 211.182; 211.160(b); 211.180(e)
  6. The company did not ensure that electronic import entry submissions declared it as the manufacturer.

    21 CFR 1.74(a)(1)

What FDA wants

FDA asks Neva Global to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence. FDA also asks for detailed component testing plans, a risk assessment of products within expiry, and high-risk component test results within 30 calendar days.

Who should pay attention

  • U.S. importers and distributors of OTC drugs made in Turkey
  • brands using contract manufacturers for OTC drug products
  • entry filers and suppliers handling drug imports from this firm

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk